Eli Lilly and Company (LLY) Thursday announced positive topline results from the QWINT-1 and QWINT-3 phase 3 studies evaluating once weekly basal insulin efsitora alfa in adults with type 2 diabetes. The studies met their primary goals.
QWINT-1 study evaluated the efficacy and safety of efsitora compared to once daily insulin glargine for 52 weeks. Adults with type 2 diabetes who are insulin naive were randomized to receive either efsitora once weekly or insulin glargine once daily. The study met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin glargine at week 52.
QWINT-3 evaluated the efficacy and safety of once weekly efsitora compared to once daily insulin degludec for 78 weeks in adults with type 2 diabetes currently treated with basal insulin. Participants were randomized to receive either efsitora once weekly or insulin degludec once daily. This study also met its primary endpoint of non-inferior A1C reduction with efsitora compared to insulin degludec at week 26.
Aditionally, in both QWINT-1 and QWINT-3, the overall safety and tolerability profile of efsitora was similar to that of daily basal insulin therapies for the treatment of type 2 diabetes.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.